The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Intrahepatic Cholangiocarcinoma: Rising Frequency, Improved Survival, and Determinants of Outcome After Resection
Abstract
BACKGROUND: Despite data suggesting a rising worldwide incidence, intrahepatic cholangiocarcinoma (IHC) remains an uncommon disease. This study analyzes changes in IHC frequency, demographics, and treatment outcome in a consecutive and single institutional cohort. METHODS: Consecutive patients with confirmed IHC seen and treated over a 16-year period were included. The trend in IHC frequency over the study period was compared with that of hilar cholangiocarcinoma patients (HCCA) seen during the same time. Demographics and patient disposition, histopathologic, treatment, recurrence, and survival data were analyzed; changes in these variables over time were assessed. RESULTS: From December 1990 through July 2006, 594 patients were evaluated (IHC = 270, HCCA = 324). Over the study period, the average annual increase in new IHC patients was 14.2% (P < 0.001). Relative to HCCA, the proportional increase in IHC was nearly 3-fold, and new IHC patients have outnumbered those with HCCA by 2:1 over the last 3 years. Conditions associated with IHC were rarely seen, with only 7 patients having a history of sclerosing cholangitis and/or inflammatory bowel disease and none with hepatolithiasis or biliary parasitic disease; however, heavy tobacco use (27%) and diabetes mellitus (16.4%) were particularly prevalent. The majority of patients were not candidates for resection, most commonly because of advanced hepatic disease. After resection (n = 82), median disease-specific survival was 36 months; recurrence was observed in 62.2% of patients at a median follow-up of 26 months, with the liver remnant involved most frequently (62.7%). Multiple hepatic tumors (P < 0.001), regional nodal involvement (P = 0.012), and large tumor size (P = 0.016) independently predicted poor recurrence-free survival. Most patients (n = 115, 73.7%) with unresectable disease were treated with chemotherapy, either systemic alone (n = 75) or combined with regional hepatic arterial floxuridine (FUDR) (n = 28). Compared with the first 10 years of the study (1990-2000), the last 6 years saw an overall improvement in disease-specific survival for all patients (22 vs. 12 months, P = 0.002), which was particularly notable for patients with unresectable disease (15 vs. 6 months, P = 0.003). CONCLUSIONS: At Memorial Sloan-Kettering Cancer Center, IHC incidence has increased dramatically in the last 16 years. Resection offers the best opportunity for long-term survival but is possible in the minority, and patients with large, node-positive or multifocal IHC seem to derive little benefit. Establishing and maintaining control of the intrahepatic disease remains the biggest problem for all IHC patients. The recent increase in survival seems largely because of improved nonoperative therapy for unresectable disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution
DeOliveira, M. L., Cunningham, S. C., Cameron, J. L., Kamangar, F., Winter, J. M., Lillemoe, K. D., Choti, M. A., Yeo, C. J., & Schulick, R. D. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000251366.62632.d3 · Cited by 1,300
Khan, S. A., Thomas, H. C., Davidson, B. R., & Taylor-Robinson, S. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67530-7 · Cited by 1,042
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
Welzel, T. M., Graubard, B. I., El–Serag, H. B., Shaib, Y. H., Hsing, A. W., Davila, J. A., & McGlynn, K. A. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.05.020 · Cited by 514
Report of the 17th Nationwide Follow‐up Survey of Primary Liver Cancer in Japan†
Ikai, I., Arii, S., Okazaki, M., Okita, K., Omata, M., Kojiro, M., Takayasu, K., Nakanuma, Y., Makuuchi, M., Matsuyama, Y., et al. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00119.x · Cited by 412
Liver fluke-associated cholangiocarcinoma
Watanapa, P., & Watanapa, W. B. (2002) · British Journal of Surgery · doi:10.1046/j.1365-2168.2002.02143.x · Cited by 303
Nathan, H., Pawlik, T. M., Wolfgang, C. L., Choti, M. A., Cameron, J. L., & Schulick, R. D. (2007) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-007-0282-0 · Cited by 245
Welzel, T. M., Mellemkjaer, L., Gloria, G., Sakoda, L. C., Hsing, A. W., Ghormli, L. E., Olsen, J. H., & McGlynn, K. A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22283 · Cited by 195
MR Imaging of Intrahepatic Cholangiocarcinoma with Pathologic Correlation
Maetani, Y., Itoh, K., Watanabe, C., Shibata, T., Ametani, F., Yamabe, H., & Konishi, J. (2001) · American Journal of Roentgenology · doi:10.2214/ajr.176.6.1761499 · Cited by 184
Hepatolithiasis associated with cholangiocarcinoma
Kubo, S., Kinoshita, H., Hirohashi, K., & Hamda, H. (1995) · World Journal of Surgery · doi:10.1007/bf00294744 · Cited by 177
Cited by
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Self-citationRazumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Bridgewater, J., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J.-W., Patel, T., Pawlik, T. M., & Gores, G. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.021 · Cited by 1,511
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.013 · Cited by 1,307
Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy
Wang, Y., Li, J., Xia, Y., Gong, R., Wang, K., Yan, Z., Wan, X., Liu, G., Wu, D., Shi, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.5984 · Cited by 1,057
Mavros, M. N., Economopoulos, K. P., Alexiou, V. G., & Pawlik, T. M. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2013.5137 · Cited by 808
Clinical diagnosis and staging of cholangiocarcinoma
Blechacz, B., Komuta, M., Roskams, T., & Gores, G. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.131 · Cited by 747
New Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626
Cholangiocarcinoma: Current Knowledge and New Developments
Blechacz, B. (2017) · Gut and Liver · doi:10.5009/gnl15568 · Cited by 485
ACG Clinical Guideline: The Diagnosis and Management of Focal Liver Lesions
Marrero, J. A., Ahn, J., & Reddy, R. K. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.213 · Cited by 477
Intrahepatic Cholangiocarcinoma: expert consensus statement
Weber, S. M., Ribero, D., O'Reilly, E. M., Kokudo, N., Miyazaki, M., & Pawlik, T. M. (2015) · HPB · doi:10.1111/hpb.12441 · Cited by 472
Self-citationMoris, D., Palta, M., Kim, C., Allen, P. J., Morse, M. A., & Lidsky, M. E. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21759 · Cited by 451
Liver resection and transplantation for intrahepatic cholangiocarcinoma
Mazzaferro, V., Gorgen, A., Roayaie, S., Droz dit Busset, M., & Sapisochin, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.020 · Cited by 355
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Alvaro, D., Gores, G. J., Walicki, J., Hassan, C., Sapisochin, G., Komuta, M., Forner, A., Valle, J. W., Laghi, A., Ilyas, S. I., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.010 · Cited by 344
Clinical presentation, diagnosis and staging of cholangiocarcinoma
Forner, A., Vidili, G., Rengo, M., Bujanda, L., Ponz‐Sarvisé, M., & Lamarca, A. (2019) · Liver International · doi:10.1111/liv.14086 · Cited by 326
Classification, Diagnosis, and Management of Cholangiocarcinoma
Razumilava, N., & Gores, G. J. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.09.009 · Cited by 312
Lunsford, K. E., Javle, M., Heyne, K., Shroff, R. T., Abdel-Wahab, R., Gupta, N., Mobley, C. M., Saharia, A., Victor, D. W., Nguyen, D. T., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30045-1 · Cited by 298
Spolverato, G., Kim, Y., Alexandrescu, S., Marques, H. P., Lamelas, J., Aldrighetti, L., Clark Gamblin, T., Maithel, S. K., Pulitano, C., Bauer, T. W., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4642-9 · Cited by 283
Recurrence after operative management of intrahepatic cholangiocarcinoma
Hyder, O., Hatzaras, I., Sotiropoulos, G. C., Paul, A., Alexandrescu, S., Marques, H., Pulitano, C., Barroso, E., Clary, B. M., Aldrighetti, L., et al. (2013) · Surgery · doi:10.1016/j.surg.2012.12.005 · Cited by 281
Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis
Ali, A. H., Tabibian, J. H., Nasser‐Ghodsi, N., Lennon, R. J., DeLeon, T., Borad, M. J., Hilscher, M., Silveira, M. G., Carey, E. J., & Lindor, K. D. (2018) · Hepatology · doi:10.1002/hep.29730 · Cited by 140
Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
Khosla, D., Misra, S., Chu, P. L., Guan, P., Nada, R., Gupta, R., Kaewnarin, K., Ko, T. K., Heng, H. L., Srinivasalu, V. K., et al. (2024) · Cancers · doi:10.3390/cancers16040801 · Cited by 44
“The most common site of relapse in intrahepatic CCA is the liver (accounting for approximately 60%), with associated extrahepatic relapse in 18.6%, followed by extrahepatic recurrence in 21% [105,106].”
BackgroundInfluentialHuang, L., Cai, J., Guo, H., Gu, J., Tong, Y., Qiu, B., Wang, C., Li, M., Xia, L., Zhang, J., et al. (2019) · Hepatology · doi:10.1002/hep.30404 · Cited by 42
Metadata
- Authors
- Endo, I., Gonen, M., Yopp, A. C., Dalal, K. M., Zhou, Q., Klimstra, D., D'Angelica, M., DeMatteo, R. P., Fong, Y., Schwartz, L., Kemeny, N., O'Reilly, E., Abou-Alfa, G. K., Shimada, H., Blumgart, L. H., & Jarnagin, W. R.
- Venue
- Annals of Surgery
- Published
- 2008-07
- Volume
- 248
- Issue
- 1
- Pages
- 84-96
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W1991701933
- Cited by
- 865
- References
- 11
- FWCI
- 26.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.